Nuwellis, Inc. (NASDAQ:NUWE) Sees Large Decrease in Short Interest

Nuwellis, Inc. (NASDAQ:NUWE) was the target of a significant decrease in short interest in January. As of January 15th, there was short interest totaling 5,056 shares, a decrease of 29.2% from the December 31st total of 7,144 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average trading volume of 159,143 shares, the short-interest ratio is currently 0.0 days. Based on an average trading volume of 159,143 shares, the short-interest ratio is currently 0.0 days. Approximately 0.4% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Several research firms have recently commented on NUWE. Wall Street Zen downgraded Nuwellis from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Nuwellis in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Nuwellis Stock Performance

Shares of Nuwellis stock traded up $0.08 on Monday, hitting $3.85. The company had a trading volume of 604,214 shares, compared to its average volume of 6,349,381. Nuwellis has a 1 year low of $1.71 and a 1 year high of $62.16. The stock has a 50 day moving average of $2.33 and a 200-day moving average of $4.01. The stock has a market capitalization of $6.39 million, a price-to-earnings ratio of -0.04 and a beta of -0.12.

Nuwellis (NASDAQ:NUWE) last announced its quarterly earnings results on Wednesday, November 12th. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of ($17.22) by $17.78. The business had revenue of $2.22 million during the quarter, compared to the consensus estimate of $2.50 million. Nuwellis had a negative return on equity of 1,367.63% and a negative net margin of 202.83%. Equities analysts anticipate that Nuwellis will post -8.17 earnings per share for the current year.

Nuwellis Company Profile

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.